Tarsus Pharmaceuticals Inc expected to post a loss of $1.20 a share - Earnings Preview

Tarsus Pharmaceuticals

07/05/2024 03:01

* Tarsus Pharmaceuticals Inc  TARS.OQ   TARS.O  is expected
to show a rise in quarterly revenue when it reports  results on
May 8 for the period ending March 31 2024
    * The Irvine California-based  company is expected to report
a
613.0% increase in revenue to $17.826 million from $2.5 million
a year ago, according to the mean estimate from 7 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Tarsus Pharmaceuticals
Inc is
for a loss of $1.20 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.3%
in the last three months. ​
    * Wall Street's median 12-month price target for Tarsus
Pharmaceuticals Inc is $58.00​, above​ its last closing price
of $37.03. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -1.39       -1.36      -1.31     Beat    3.9
 Sep. 30 0001  -1.29       -1.37      -1.28     Beat    6.3
 Jun. 30 2023  -1.06       -1.08      -1.17     Missed  -8.5​
 Mar. 31 2023  -0.92       -0.94      -0.88     Beat    6.9
 ​​Dec.                    -0.69      -0.49     Beat    29
 31 2022                                                
 Sep. 30 2022  -0.88       -0.97      -0.84     Beat    13.7​
 Jun. 30 2022  -0.61       -0.59      -0.24     Beat    59.4
 Mar. 31 2022  -1.06       -0.92      -0.98     Missed  -6.8
 This summary was machine generated May 7 at 02:01 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)